Anti-leukemia Effect of Oridonin on T-cell Acute Lymphoblastic Leukemia

GUO Yong, SHAN Qing-qing, GONG Yu-ping. et al

Abstract

To investigate the antileukemia effect of oridonin on T-cell acute lymphoblastic leukemia cell line CEM. Methods Human T-cell acute lymphoblastic leukemia cell line CEM was cultured in vitro. The 50% inhibition concentration (IC50) of oridonin against CEM cells was examined using modified MTT assay. The cellular morphologic changes were observed using a light microscope. The percent of apoptosis of CEM cells after drug treatment was evaluated by flow cytometric analysis. The active levels of AKT/mTOR, RAF/MEK/ERK, STAT5 signaling pathways and the expression levels of Bcl-2 and BAX were examined by Western blot. Results Oridonin inhibited the growth of CEM cells in time- and dose-dependent manner and the IC50 of oridonin was (7.37±1.99) μmol/L after 72 h treatment. The cellular membrane of CEM cells treated with oridonin became unsharp, some of them disintegrated. Oridonin induced apoptosis in CEM cells and the percent of apoptosis rate after 0, 5, 7.5, 10 μmol/L oridonin treatment for 24 h were (4.8±2.11)%, (19.03±2.54)%,(40.27±3.31)% and (57.23±6.69)% respectively. Oridonin inhibited activation of mTOR, P70S6, 4EBP1, RAF, ERK and STAT5 signaling protein, which were constitutively activated in CEM cells, however, oridonin had no inhibitory effect on AKT kinase. Oridonin down-regulated the level of anti-apoptotic protein Bcl-2 and up-regulated the expression of pro-apoptotic protein Bax. Conclusion Oridonin exerted antileukemia effect in CEM cells by inhibiting the activation of mTOR/P70/4EBP1, RAF/ERK and STAT5 signaling pathways, down-regulating the expression of Bcl-2 and up-regulating the expression of BAX.

 

Keywords: CEM Antileukemia effect, Oridonin, AKT/mTOR RAF/MEK/ERK STAT5 

 

Full Text:

PDF


References


Zhao WL. Targeted therapy in T-cell malignancies; dysregulation of the cellular signaling pathways. Leukemia, 2010;24(1): 13-21.

Guo Y, Shan Q. Gong Y,et al. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph + acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol Ther. 2012; 13 (13):1244-1254.

Zhao YM, Zhou Q, Xu Y, et al. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Acta Pharmacol Sin, 2008;29(4) :481-488.

Avellino R. Romano S, Parasole R, et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood,2005; 106(4): 1400-1406

Wei G, Twomey D. Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell, 2006; 10 (4 ); 331- 342.

Chiarini F, Fala F. Tazzari PL, et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res,2009;69(8) :3520-3528.

Chiarini F. Del Sole M, Mongiorgi S, et al. The novel АКТ inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia, 2008; 22 (6): 1106-1116.

Nyakern M, Cappellini A, Mantovani I, et al. Synergistic induction of apoptosis in human leukemia T cells by the АКТ inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther,2006;5(6):1559-1570.

Fala F, Blalock WL, Tazzari PL, et al. Proapoptotic activity and chemosensitizing effect of the novel АКТ inhibitor (2S)-1- (1 H-Indol-3-yl)-3-[5-( 3-methyl-2H-indazol-5-yl )-pyridin-3-yl] oxypropan2-ami ne (A443654) in T-cell acute lymphoblastic leukemia. Mol Pharmacol,2008;74(3) :884-895.

Hussain AR, Al-Rasheed M. Manogaran PS, etui. Curcumin induces apoptosis via inhibition of Pl3-kinase/AKT pathway in acute T-cell leukemias. Apoptosis,2006; 11(2) ;245-254.

Nasr R, El-Sabban MP3, Karam JA, et al. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T- cell lymphomas and HTLV-I associated adult T-cell leukemia/ lymphoma. Oncogene,2005;24(3):419-430.

Lee J, Suh C, Kang HJ, et al. Phase I studyof proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol. 2008; 19(12):2079-2083.

Zhou GB, Kang H, Wang L. et al. Oridonin, a diterpenoid extracted from medicinal herbs, targets AMLl-ETO fusion protein and shows potent antitumor activity with low adverse effectson t(8; 21) leukemia in vitro and in vivo. Blood. 2007; 109(8)j3441-3450.


Refbacks

  • There are currently no refbacks.